Loss Narrowing Veils Revenue Stall — CGFMU Driving Optics

On its face, the quarter looks like recovery: loss fell from ₹153 crore to ₹34 crore, a reduction of 85.8%. But pull back one layer and the story narrows. Of that gain, ₹75 crore (63%) came from CGFMU provision relief—a policy-driven accounting benefit, not operational leverage. Strip it out and the organic loss reduction is only ₹44 crore; without the guarantee-scheme relief, the loss would have been ₹109 crore. More: revenue stands at ₹883.6 crore, up just 0.3% year-on-year. The bank claimed 49% disbursement momentum, yet the loan book grew near-zero in the quarter after write-offs and rundown. Pain is easing, but momentum is not.

Credit cost—the main driver—fell 630 basis points year-on-year, from 8.5% to 2.3%, a structural improvement in asset quality. Fresh NPA slippages halved to ₹125 crore (down 69% YoY), and GNPA ratio contracted 550 basis points to 5.9%. These are real. Yet the provision relief from CGFMU, while legitimate, is exogenous: management guided that the guarantee scheme covers 80% of new JLG and MBBL disbursements, with 72.75% claim coverage and zero risk-weight benefits. This lifts the bottom line in the near term but masks underlying portfolio stress—retail SARFAESI recoveries are still slow (6–7 months per case), and the bank's own legacy NPA pool (₹656 crore pre-April '25, 66% provisioned) is ring-fenced, not gone.

On the upside: cost of funds fell 40 basis points year-on-year to 7.7%, buoyed by deposit mix repricing (CASA up 15% YoY, senior citizen term rates cut from 9.1% to 8.25%). Operating profit (PPOP) is ₹64 crore, five times Q4's ₹12 crore. The trajectory is upward. But profitability is not yet positive, and the bank is still burning cash on the net income line despite positive PPOP—a warning sign that provisions and other charges are still heavy.

Secured lending target raised to 55%. The bank now holds 51% of its portfolio in secured assets (MSME, housing, business banking, CV & CE, gold), up from 45% a year ago. This is a structural shift: unsecured JLG/MBBL, which was 88% of the book in 2020, is now 26%. The rationale is clear—volatility reduction and diversification—but it also implies lower yields. MSME yield is ~18%, housing yields lower, and the overall margin is compressed versus the prior unsecured-heavy mix.

CGFMU guarantee scheme now guardrails 80% of new MFI disbursements. This is new structural support: 72.75% claim coverage plus zero risk-weight cap (15% of portfolio gets zero risk weight for regulatory capital). It reduces the bank's tail risk on fresh JLG/MBBL stress and provides a provision-relief cushion. However, it also highlights that management believes the portfolio remains stressed enough to need guardrails on new business—not an image of clean underwriting.

Cost of funds repricing unfolding progressively. The 40 basis-point benefit is real; deposit costs are falling. Senior citizen rates cut from 9.1% peak to 8.25%; general term rates from 8.5% to 8.1%. Management guided that further repricing benefit is expected in Q2–Q3 as maturing deposits roll into lower rates. This is a lever for NIM stability, but it is also customer-rate driven, not margin-expansion driven.

Credit cost guidance narrowed to 3–3.5% (rest of FY27), then 2–2.5% by FY28. Management flagged Q1's low 2.3% as seasonally anomalous and guided conservatively to the upper end for H2. This is a realistic hedge: fresh slippages are down, but portfolio stress remains, and collection seasonality peaks in H2. The FY28 target (2–2.5%) is maintained, signaling confidence in the structural recovery story.

Loan growth guidance reaffirmed: 25–30% annual growth. Despite Q1 near-flat portfolio growth, management held firm on the full-year target. The logic: Q1 is seasonally weak; Q4 saw 30% disbursement growth, Q1 saw 49% disbursement growth. The write-off and rundown headwind is acknowledged but expected to ease as the quality cycle normalizes. No change in confidence; execution risk remains high.

The stock closed at ₹14.04 (as of Aug 14), down 36% from its all-time high of ₹22.03 and off the 52-week low of ₹10.12 by 39%. It trades below its 20-day, 50-day, and 200-day moving averages (₹14.4, ₹14.28, ₹14.42, respectively), signaling a downtrend. RSI is 37.9 (neutral, not oversold). This repricing reflects the reset: from a story of recovery-at-scale to a story of recovery-if-execution-holds.

Post-result price action faded. On day 1 post-announcement, the stock fell 0.41%. By day 5, it was down 2.94%. The market took the announcement in stride—no pop, no crash—and then repriced downward. Delivery was 54.5% on day 1, suggesting some profit-taking. This is the street's own verdict: the loss improvement is as expected; revenue stall is a disappointment; guidance held but credibility on execution is not yet there.

FII participation is up sharply, but timing matters. FII holding rose from near-zero (1.85% in FY25 Q1) to 11.9% in Q1 FY27—a structural re-entry into the stock post-stress cycle. This suggests institutional belief in the recovery narrative and long-term compounding potential. However, DII holdings remain flat at 9.55%, suggesting domestic institutions are waiting for proof. Promoter stake is stable at 42.67%, no dilution signaled. The FII entry post-result fade (not pre-result run-up) suggests late-cycle conviction, not front-running confidence.

Valuation context: at a 52-week drawdown of 36%, the stock has reset from "recovery story at scale" (₹22) to "recovery if executed" (₹14). This is fair repricing given the soft Q1 P&L and unproven execution on 25–30% growth. The stock is not in free fall (RSI not oversold, volume normal); it is repricing durably downward to reflect execution risk.